# Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

> **NCT00702299** · PHASE1 · COMPLETED · sponsor: **University of Arizona** · enrollment: 15 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** paclitaxel
- **DRUG:** pemetrexed disodium
- **OTHER:** biologic sample preservation procedure

## Key facts

- **NCT ID:** NCT00702299
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702299, "Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00702299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*